Published in Curr Opin Gastroenterol on January 01, 2007
The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res (2008) 1.75
Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol (2008) 1.26
Wnt/beta-catenin signaling in oral tissue development and disease. J Dent Res (2010) 1.20
Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res (Phila) (2011) 1.19
The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol (2011) 1.18
NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide (2008) 1.16
Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis (2009) 1.16
Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res (2010) 1.15
Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther (2011) 1.14
Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis (2010) 1.12
The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol (2012) 1.08
Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis (2008) 1.01
Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res (2008) 0.97
Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studies. PLoS One (2012) 0.89
Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling. Cancer Lett (2008) 0.86
Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action. Exp Cell Res (2011) 0.85
NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts. Carcinogenesis (2008) 0.80
The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin. Int J Oncol (2009) 0.79
Comparative proteomic analysis of cysteine oxidation in colorectal cancer patients. Mol Cells (2013) 0.78
Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats. Int J Oncol (2008) 0.78
The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. J Pharmacol Exp Ther (2015) 0.78
NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis? PPAR Res (2008) 0.77
Phospholipid remodeling and eicosanoid signaling in colon cancer cells. Indian J Biochem Biophys (2014) 0.76
Mouse models of DNA mismatch repair in cancer research. DNA Repair (Amst) (2015) 0.76
In vitro evaluation of novel N-acetylalaninate prodrugs that selectively induce apoptosis in prostate cancer cells. BMC Cancer (2014) 0.76
Therapeutic potential of hydrazones as anti-inflammatory agents. Int J Med Chem (2014) 0.75